Hologic, Inc. (HOLX)
NASDAQ: HOLX · Real-Time Price · USD
63.27
-0.12 (-0.19%)
Mar 3, 2025, 4:00 PM EST - Market closed
Hologic Employees
Hologic had 6,990 employees as of September 30, 2023. The number of employees increased by 46 or 0.66% compared to the previous year.
Employees
6,990
Change (1Y)
46
Growth (1Y)
0.66%
Revenue / Employee
$577,825
Profits / Employee
$106,438
Market Cap
14.20B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 6,990 | 46 | 0.66% |
Sep 24, 2022 | 6,944 | 239 | 3.56% |
Sep 25, 2021 | 6,705 | 891 | 15.33% |
Sep 26, 2020 | 5,814 | -664 | -10.25% |
Sep 28, 2019 | 6,478 | 226 | 3.61% |
Sep 29, 2018 | 6,252 | 19 | 0.30% |
Sep 30, 2017 | 6,233 | 900 | 16.88% |
Sep 24, 2016 | 5,333 | 43 | 0.81% |
Sep 26, 2015 | 5,290 | -61 | -1.14% |
Sep 27, 2014 | 5,351 | -264 | -4.70% |
Sep 28, 2013 | 5,615 | -542 | -8.80% |
Sep 29, 2012 | 6,157 | 1,138 | 22.67% |
Sep 24, 2011 | 5,019 | 799 | 18.93% |
Sep 25, 2010 | 4,220 | 261 | 6.59% |
Sep 26, 2009 | 3,959 | 26 | 0.66% |
Oct 25, 2008 | 3,933 | 353 | 9.86% |
Nov 12, 2007 | 3,580 | 1,963 | 121.40% |
Nov 17, 2006 | 1,617 | 747 | 85.86% |
Nov 19, 2005 | 870 | 109 | 14.32% |
Nov 30, 2004 | 761 | 39 | 5.40% |
Nov 30, 2003 | 722 | -7 | -0.96% |
Nov 30, 2002 | 729 | -51 | -6.54% |
Nov 30, 2001 | 780 | -66 | -7.80% |
Nov 30, 2000 | 846 | 410 | 94.04% |
Nov 30, 1999 | 436 | 40 | 10.10% |
Nov 30, 1998 | 396 | 57 | 16.81% |
Nov 30, 1997 | 339 | 45 | 15.31% |
Nov 30, 1996 | 294 | 103 | 53.93% |
Nov 30, 1995 | 191 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
HOLX News
- 6 days ago - Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference - Business Wire
- 12 days ago - Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software - Business Wire
- 13 days ago - Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay - Business Wire
- 26 days ago - Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Hologic cuts annual revenue forecast on weak demand for breast health products - Reuters
- 26 days ago - Hologic Announces Financial Results for First Quarter of Fiscal 2025 - Business Wire
- 5 weeks ago - New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide - Business Wire
- 6 weeks ago - Hologic: Reasonably, But Not Compellingly Valued - Seeking Alpha